Print

RedHill Biopharma Ltd. Commences a Pivotal Bioequivalence Trial with RHB-103 (An Oral Thin Film for the Treatment of Migraine); Subjects' Recruitment Completed; First Dose Administered; Results Expected within Months  
4/24/2012 10:29:21 AM

TEL AVIV, Israel--(BUSINESS WIRE)--RedHill Biopharma Ltd. (TASE: RDHL), an emerging Israeli biopharmaceutical company focusing primarily on development of late clinical-stage new formulations and combinations of existing drugs, has announced today the commencement of a pivotal bioequivalence clinical trial with RHB-103, an oral thin-film formulation of a leading triptan for the treatment of acute migraine. RedHill has completed screening and recruitment of all subjects for this clinical trial and announced subjects' first dosing on April 23rd, 2012.
//-->